Investors and Media

Idera is advancing to the clinic in autoimmune diseases and certain genetically defined forms of B-cell lymphoma: activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL), Waldenström’s macroglobulinemia and others. Its lead drug candidate, IMO-8400, is designed to modulate immune responses through Toll-like receptors (TLRs).

Recent News

Aug 24, 2016Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense TechnologyRead MoreAug 12, 2016Idera to Present at the 2016 Wedbush PacGrow Healthcare ConferenceRead MoreAug 02, 2016Idera Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate UpdateRead More

Webcast

August 16, 2016 at 12:45 p.m. ETIdera at the 2016 Wedbush PacGrow Healthcare Conference

Upcoming Events

There are currently no events scheduled.

CORPORATE PRESENTATION

There are currently no items available.
Data provided by Nasdaq. Minimum 15 minutes delayed.